Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25482268 | 0.81 | ADRA2C (0.48) | KMT2AMEN1FDPSLMNAGABRA1 | |
| SCHEMBL3456139 | 0.78 | KMT2A (0.45) | KMT2AMEN1LMNA | |
| SCHEMBL29194433 | 0.77 | ADRA2A (0.48) | KMT2AMEN1LMNAADRA2C | |
| SCHEMBL4063363 | 0.77 | FDPS (0.48) | KMT2AMEN1FDPSLMNAOPRK1 | |
| SCHEMBL1044189 | 0.77 | KMT2A (0.54) | KMT2AMEN1FDPSEGLN1KDM4E | |
| SCHEMBL6284886 | 0.76 | MEN1 (0.48) | KMT2AMEN1OPRK1GABRA1GABRG2 | |
| Hydrochloric Acid SCHEMBL1875423 | 0.75 | KMT2A (0.53) | KMT2AMEN1FDPSEGLN1KDM4E | |
| Ethylene SCHEMBL28111857 | 0.74 | KMT2A (0.51) | KMT2AMEN1FDPSEGLN1KDM4E | |
| Formic Acid SCHEMBL30454816 | 0.73 | KMT2A (0.44) | KMT2AMEN1FDPSOPRK1KDM4E | |
| SCHEMBL14355877 | 0.73 | NCF1 (0.51) | KMT2AMEN1ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021483-A1 | Platinum (IV) Complexes | PLATCO TECHNOLOGIES (PROPRIETARY) LIMITED (ZA) | 2011-01-27 | — | — | US | disclosed |
| CN-101778857-A | Platinum (IV) complex compound | PLATCO TECHNOLOGIES PROPRIETAR | 2010-07-14 | — | — | CN | disclosed |
| EP-2170913-A1 | PLATINUM (IV) COMPLEXES | Platco Technologies (Proprietary) Limited (ZA) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008155727-A1 | PLATINUM (IV) COMPLEXES | PLATCO TECHNOLOGIES (PROPRIETARY) LIMITED (ZA) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021483-A1 | Platinum (IV) Complexes | OTC, OAT, SLC25A11 | KMT2A 3593/4885MEN1 974/4885FDPS 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.